You are here

Management of Targeted Therapies: digestive toxicities

By Christophe Tournigand, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

35 - Christophe Tournigaud ANG

Christophe Tournigand provides an overview of the most common toxicities of the digestive system as well as the drugs and targeted therapies that cause them. These toxicities are important as they can require dose reductions, have an impact on pharmacokinetics and affect the patient’s quality of life. Hepatic toxicities can be caused by direct toxicity on the hepatic parenchyma, drug interaction, immunoallergic mechanisms or alteration of the underlying hepatic function. Other toxicities include pancreatic toxicities, perforations and diarrhea. Diarrhea is the most problematic toxicity for the patients and should not be underestimated as it can lead to dehydration and fatigue.


Christophe Tournigand, Hôpital H. Mondor, Créteil, France

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo